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Among patients with multiple sclerosis, discontinuing highly effective disease-modifying
treatments can potentially lead to severe disease recurrence, especially cessation of nata-
lizumab and ﬁngolimod. Similar to ﬁngolimod, siponimod is a sphingosine-1-phosphate
receptor modulator that inhibits the egress of a lymphocyte subpopulation from lymph
nodes. In the present case report, we describe a patient with MS who experienced substantial
disease exacerbation after withdrawal from siponimod.
© 2017 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Among patients with multiple sclerosis (MS), discontinuing
highly effective disease-modifying treatments can potentially
lead to severe disease recurrence, especially cessation of
natalizumab and ﬁngolimod [1]. Siponimod is a drug that has
been investigated in patients with relapsing-remitting MS
(RRMS) and secondary progressive MS (SPMS) [2]. It is a
sphingosine-1-phosphate (S1P) receptor modulator that inhi-
bits the egress of a lymphocyte subpopulation from lymph
nodes. In contrast to ﬁngolimod, siponimod selectively binds
to only two S1P receptors (S1P1 and S1P5), does not require* Corresponding author at: Second Department of Neurology, Institut
Poland.
E-mail address: czlonkow@ipin.edu.pl (A. Członkowka).
http://dx.doi.org/10.1016/j.pjnns.2017.10.001
0028-3843/© 2017 Polish Neurological Society. Published by Elsevier Sin vivo phosphorylation, and has a shorter half-life and
elimination time. In the present case report, we describe a
patient with MS who experienced substantial disease exacer-
bation after withdrawal from siponimod.
2. Case report
A 24-year-old woman was diagnosed with RRMS after
experiencing two relapses over a period of four years[annual-
ized relapse rate (ARR) = 0.5, Expanded Disability Status Scale
(EDSS) = 2.5]. Following the second relapse (December 2009),
the patient was enrolled in a clinical trial with siponimod [2].e of Psychiatry and Neurology, ul. Sobieskiego 9, 02-957 Warsaw,
p. z o.o. All rights reserved.
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lesion in the left forntal lobe (Fig. 1A–D). She remained in this
trial until its completion in July 2016. During the last four years
of the trial, she received siponimod at a daily dose of 2 mg.
Upon trial completion, the patient was in clinical remission
(EDSS = 1.5, on treatment ARR = 0.28). Brain MRI revealed a
gadolinium-enhancing lesion in the right frontal lobe; howev-
er, the lesion count on FLAIR images was comparable to that
on siponimod initiation (Fig. 1E–H).
After 10 weeks without any disease-modifying treatment,
we started dimethyl fumarate as the patient preferred oral
treatment and other oral agents were not available under
reimbursement arrangements. However, two weeks later, she
was admitted due to a relapse with left-sided hypoesthesia
and left-sided pyramidal signs (EDSS = 2.5). MRI revealed
multiple (over 10) gadolinium-enhancing lesions in both brain
hemispheres and in the cervical spinal cord (Fig. 1I–U). The
lymphocyte count had returned to a normal level (1.81 K/ml)
compared to a level of 0.42 K/ml on siponimod. The patient
received intravenous methylprednisolone (1 g for 5 days) and
improved (EDSS = 2.0). Despite further treatment with dimeth-
yl fumarate, 6 weeks later, the patient presented with gait
worsening, paresthesia in the lower extremities, and
hypoesthesia in the anogenital area (EDSS = 3.0). Repeated
treatment with intravenous methylprednisolone was admin-
istered on an outpatient basis, which led to reversal of relapse
symptoms (EDSS = 2.0). Because second-line treatments (e.g.,
natalizumab, ﬁngolimod) were not available under reimburse-
ment arrangements, the patient stayed on dimethyl fumarate.
3. Discussion
In patients with MS, discontinuation of highly effective
disease-modifying treatments can lead to substantial disease
recurrence. Prior reports of such recurrence have most often
followed withdrawal of natalizumab and ﬁngolimod. Notably,
siponimod and ﬁngolimod are both S1P receptor modulators
and, thus, it could be suspected that discontinuation of
siponimod may also lead to disease exacerbation. Additional-
ly, siponimod will likely be indicated for use in patients with
SPMS who also experience increased disease activity after
withdrawal from S1P receptor modulators [3].
To our knowledge, this is the ﬁrst case report to describe
disease exacerbation in a patient with MS following siponimod
discontinuation. Our patient exhibited disease reactivation
three months after siponimod treatment cessation, which is
similar to prior reports involving ﬁngolimod cessation [4]. Our
patient's ﬁrst relapse after treatment withdrawal did not lead
to severe neurological impairment; however, MRI revealed
multiple gadolinium-enhancing lesions in both brain hemi-
spheres and the cervical spinal cord. Despite further treatment
with dimethyl fumarate, six weeks later, the patient experi-
enced another relapse with a more signiﬁcant deﬁcit.
Notably, the disease reactivation in our patient occurred
upon reconstitution of the lymphocyte count, which has also
been reported in patients with MS who experienced disease
reactivation after ﬁngolimod discontinuation. This observa-
tion, along with the similar temporal relationship between
treatment discontinuation and disease reactivation, mayindicate that analogous processes lead to disease recurrence
after withdrawal of siponimod and ﬁngolimod. Cessation of
siponimod or ﬁngolimod likely leads to an egress of lympho-
cytes from lymph nodes, restoration of the lymphocyte count,
and immune inﬁltration of the central nervous system. This
process can be interpreted in the context of immune
reconstitution inﬂammatory syndrome (IRIS), in which neu-
rological symptoms develop due to an exaggerated immune
system response, particularly towards previously silent
infections [5]. However, without speciﬁc criteria, it is difﬁcult
to differentiate between IRIS and the return of spontaneous
disease activity when dealing with a primary immune-
mediated disease, such as MS.
No factors have yet been identiﬁed as predicting the
occurrence of substantial disease reactivation after discontin-
uation of treatment with S1P receptor modulators. However, it
is notable that the presently described patient had a
gadolinium-enhancing lesion in her brain at the time of
treatment termination, despite being in clinical remission. In
future studies, it would be informative to investigate whether
the presence of gadolinium-enhancing lesions is associated
with a higher risk of signiﬁcant exacerbation in patients with
MS who discontinue S1P receptor modulators. Moreover, it
may be noteworthy that the exacerbation observed in our
patient occurred despite treatment with dimethyl fumarate.
Similar ﬁndings have been reported in patients who discon-
tinued ﬁngolimod and were later switched to dimethyl
fumarate; however, rescue treatment with rituximab also
failed to prevent disease recurrence in a patient with MS after
ﬁngolimod cessation [1,4].
4. Conclusion
In conclusion, discontinuation of siponimod treatment can
provoke substantial disease reactivation in patients with MS.
This observation underscores the need to identify risk factors
of substantial disease recurrence in patients with MS who
discontinue S1P receptor modulators. Moreover, it is impor-
tant to develop effective disease-modifying treatments or
alternative management strategies that can be used after
discontinuation of S1P receptor modulators in patients with
RRMS or SPMS.
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